Conradi L, Treede H, Baldus S, Seiffert M, Blankenberg S, Reichenspurner H
Universitäres Herzzentrum Hamburg, Klinik und Poliklinik für Herz- und Gefäßchirurgie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Herz. 2011 Dec;36(8):677-85. doi: 10.1007/s00059-011-3531-7.
Surgical mitral valve repair has constantly evolved to become the standard of care for severe mitral regurgitation (MR) with superior acute and long-term results compared to valve replacement. Minimally-invasive surgical techniques have been successful in reducing operative trauma while yielding equivalent or even superior results compared to the conventional sternotomy approach. However, due to elevated operative risk a growing proportion of patients are not referred for surgery, especially elderly patients with reduced ventricular function and functional MR who often present with relevant comorbidities. It is for these patients that transcatheter-based therapies may represent an attractive option. While most interventional techniques are still in experimental or early clinical stages of development, relevant clinical experience has been gained with the MitraClip® device. For successful implementation of a patient-centered mitral valve program, integration of surgical and interventional treatment modalities within a heart center is of paramount importance. This is best accomplished by an interdisciplinary dedicated heart team consisting of cardiologists and cardiac surgeons.
外科二尖瓣修复术不断发展,已成为重度二尖瓣反流(MR)的治疗标准,与瓣膜置换相比,其急性和长期效果更佳。微创外科技术已成功减少手术创伤,与传统胸骨切开术相比,效果相当甚至更优。然而,由于手术风险升高,越来越多的患者未被转诊接受手术,尤其是心室功能减退和功能性MR的老年患者,他们往往伴有相关合并症。对于这些患者,基于导管的治疗可能是一个有吸引力的选择。虽然大多数介入技术仍处于实验或早期临床开发阶段,但已通过MitraClip®设备积累了相关临床经验。为成功实施以患者为中心的二尖瓣治疗方案,心脏中心内手术和介入治疗方式的整合至关重要。这最好由心脏病专家和心脏外科医生组成的跨学科专业心脏团队来完成。